Publications

Ruhollah Moussavi-Baygi, Matthew J. Ryan, Woogwang Sim, Samuel B. Hoelscher, Valbona Luga, Arun A. Chandrakumar, Lore Hoes, Junghwa Cha, Young Sun Lee, Katelyn Herm, Ben Doron, C.K. Cornelia Ding, Bradley A. Stohr, Peng Jin, Tejasveeta Nadkarni, Xiangyi Fang, Melita Haryono, An Nguyen, Wouter R. Karthaus, Charles Sawyers, Felix Y. Feng, Hani Goodarzi, Rohit Bose. Stochastically Emergent Tumors offer in vivo whole genome interrogation of cancer evolution from non-malignant precursors bioRxiv. 2025. PMID:

Johri S, Bi K, Titchen BM, Fu J, Conway J, Crowdis JP, Vokes NI, Fan Z, Fong L, Park J, Liu D, He MX, Van Allen EM. Dissecting tumor cell programs through group biology estimation in clinical single-cell transcriptomics. Nature communications. 2025. PMID: 40025015

Fasching PA, Slamon D, Nowecki Z, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Chan A, Chia S, Martín M, Rugo HS, Loi S, Hurvitz S, Untch M, Afenjar K, Fresco R, Danyliv A, Ferrusi I, Li Z, Hortobagyi G. Health-related quality of life in patients with HR+/HER2- early breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor: results from the NATALEE trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 40019493

Facon T, Moreau P, Weisel K, Goldschmidt H, Usmani SZ, Chari A, Plesner T, Orlowski RZ, Bahlis N, Basu S, Hulin C, Quach H, O'Dwyer M, Perrot A, Jacquet C, Venner CP, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Cook G, Wang G, Pei H, Krevvata M, Carson R, Borgsten F, Kumar SK. Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025. PMID: 40016302

Arias-Badia M, Chen P, Lwin YM, Srinath A, Lyu A, Fan Z, Kwek SS, Luong DN, Setayesh A, Sakamoto M, Clark M, Lea A, Wolters RM, Goodearl A, Harding FA, Gorman JV, Ritacco W, Fong L. Sequential JAK inhibition enhances anti-tumor immunity after combined anti-PD-1 and anti-CTLA4. JCI insight. 2025. PMID: 40014402

Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2025. PMID: 40016449

Zhu X, Ding CC, Aggarwal RR. Emerging Therapeutic Targets of Neuroendocrine Prostate Cancer. Current oncology reports. 2025. PMID: 40011325

Maya M Arce, Jennifer Umhoefer, Nadia Arang, Sivakanthan Kasinathan, Jacob W Freimer, Zachary Steinhart, Haolin Shen, Mineto Ota, Anika Wadhera, Minh T.N Pham, Rama Dajani, Dmytro Dorovsky, Yan Yi Chen, Qi Liu, Brian R Shy, Julia Carnevale, Ansuman T Satpathy, Nevan J Krogan, Jonathan K Pritchard, Alexander Marson. Abstract PR008: CD4+ T cell rest and activation is enabled by centralized control of state specific regulatory genes. Cancer immunology research. 2025. PMID:

Sharifi MN, Feng E, Rydzewski NR, Taylor AK, Sperger JM, Shi Y, Helzer KT, Bootsma ML, Carreno V, Chang AH, Nunamaker LA, Blitzer GC, Shang TA, Subramanian A, Bjartell A, Josefsson A, Wikström P, Feng E, Kohli M, Yang R, Dehm SM, Small EJ, Aggarwal R, Quigley DA, Lang JM, Zhao SG, Sjöström M. Adverse prognosis gene expression patterns in metastatic castration-resistant prostate cancer. Molecular oncology. 2025. PMID: 39985777

Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, Dunbar RL, Ketchum SB, Tardif JC, Martens FMAC, Ballantyne CM, Szarek M, Mason RP, REDUCE-IT Investigators. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. Journal of the American Heart Association. 2025. PMID: 39968782

Galsky MD, Autio KA, Cabanski CR, Wentzel K, Graff JN, Friedlander TW, Howes TR, Shotts KM, Densmore J, Spasic M, Da Silva DM, Chen RO, Lata J, Skolnik J, Keler T, Yellin MJ, LaVallee TM, Fairchild J, Boffo S, O'Donnell-Tormey J, Dugan U, Bhardwaj N, Subudhi SK, Fong L. Clinical and Translational Results from PORTER, a Multi-cohort Phase 1 Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 39964352

Munshi PN, Olin RL, Wall S, McCurdy SR, Al-Juhaishi T, Baker J, Bhatt VR, Chokr N, Dahi P, DeFilipp Z, Espinoza-Gutarra M, Farhan S, Gowda L, Hamilton BK, Inamoto Y, Jayani R, Kharfan-Dabaja MA, Lin R, Meyers G, Mishra A, Murthy HS, Nawas M, Rosko AE, Ruiz M, Sorror ML, Sung AD, Carpenter PA, Hamadani M, Artz AS. US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or CAR T- cell therapy: An ASTCT Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines. Transplantation and cellular therapy. 2025. PMID: 39961473

Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, Wang G, Gupta-Werner N, Kaila S, Pei H, Matt K, Gries KS, Carson R, Borgsten F, Weisel K. Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes. European journal of haematology. 2025. PMID: 39952901

Locke FL, Mahmoudjafari Z, Kebriaei P, Gardner RA, Frigault MJ, Frey N, Komanduri KV, Perales MA, Nikiforow S. Awakening from REMS: ASTCT 80/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T Cells. Transplantation and cellular therapy. 2025. PMID: 39954962

Norweg A, Oh C, DiMango A, Hofferber B, Spinner M, Stavrolakes K, Pavol M, Lindenauer P, Murphy CG, Simon NM. Mind the Breath: Feasibility of Capnography-Assisted Learned Monitored (CALM) Breathing for Dyspnea Treatment. Journal of cardiopulmonary rehabilitation and prevention. 2025. PMID: 39976559

Bidkar AP, Peter R, Wadhwa A, Bobba KN, Bidlingmaier S, Meher N, Chou J, Greenland N, Dasari C, Naik S, Raveendran A, Basak M, Camara Serrano JA, Steri V, Kogan S, Oskowitz A, He J, Wilson DM, Aggarwal R, Sriram R, VanBrocklin HF, Seo Y, Liu B, Flavell RR. Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. PMID: 39945595

Jeung J, Nguyen A, Martinez J, Zhang L. A Primary Care Group Resilience Intervention Promotes Child and Caregiver Behavioral Health. JMIR pediatrics and parenting. 2025. PMID: 39931025

David Yoonsuk Oh, Deepak Kilari, Christopher Darr, Kevin Kayvan Zarrabi, Jessica E. Hawley, Russell Kent Pachynski, Scott T. Tagawa, Yuanquan Yang, Simon Buetikofer, Qing Xia, Gunhild Von Amsberg. A phase 1b, open-label, multicenter study of xaluritamig in patients with newly diagnosed localized intermediate- or high-risk prostate cancer in the neoadjuvant setting. Journal of Clinical Oncology. 2025. PMID:

Denkert C, Rachakonda S, Karn T, Weber K, Martin M, Marmé F, Untch M, Bonnefoi H, Kim SB, Seiler S, Bear HD, Witkiewicz AK, Im SA, DeMichele A, Pehl A, Van't Veer L, McCarthy N, Stiewe T, Jank P, Gelmon KA, García-Sáenz JA, Westhoff CC, Kelly CM, Reimer T, Felder B, Olivé MM, Knudsen ES, Turner N, Rojo F, Schmitt WD, Fasching PA, Teply-Szymanski J, Zhang Z, Toi M, Rugo HS, Gnant M, Makris A, Holtschmidt J, Nekljudova V, Loibl S. Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping. Cancer cell. 2025. PMID: 39933898

Zarrabi KK, Saxena A, Mouw KW, Koshkin VS, Friedlander T. Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present, and Future of Antibody-Drug Conjugate Development in Advanced Urothelial Carcinoma. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2025. PMID: 39913872